Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07838506 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase 3, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Study Assessing the Safety and Efficacy of Urcosimod Ophthalmic Solution in Participants With Neuropathic Corneal Pain (NCP).

Study acronym: NEPTUNE
StatusNot Yet Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoint reworded 1 of 1 changed
See other at-risk trials from Okyo Pharma Ltd

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoint(s) modified
    • Interventions modified
    • Secondary endpoints revised (3)
    • Study site revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is testing a new investigational study drug called Urcosimod Ophthalmic Solution for the treatment of Neuropathic Corneal Pain (NCP).
Trial Details
NCT Number NCT07838506
Lead Sponsor Okyo Pharma Ltd
Conditions
(from sponsor)		 Neuropathic Corneal Pain
Related terms Eye Pain
Enrollment 111 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov